Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

Baird says Allogene Therapeutics’s (ALLO) cemacabtagene ansegedleucel data update is positive. The firm is “quite encouraged” by the update, ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Allogene Therapeutics (ALLO – Research ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Allogene Therapeutics Inc . (NASDAQ:ALLO) stock has tumbled to $1.73, hitting new lows as the biotechnology firm faces a tough market environment. With a market capitalization of $377 million, the ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on ...

Allogene Therapeutics Inc . (NASDAQ:ALLO) stock has reached a new 52-week low, touching down at $1.98. According to InvestingPro data, the company maintains a strong ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic ...